PT - JOURNAL ARTICLE AU - Harte, Anna AU - Ghasemian, Ehsan AU - Pickering, Harry AU - Houghton, Joanna AU - Chernet, Ambahun AU - Sata, Eshetu AU - Yismaw, Gizachew AU - Zeru, Taye AU - Tadesse, Zerihun AU - Callahan, E. Kelly AU - Nash, Scott D. AU - Holland, Martin TI - Unravelling <em>Chlamydia trachomatis</em> Diversity in Amhara, Ethiopia: MLVA-<em>ompA</em> Sequencing as a Molecular Typing Tool for Trachoma AID - 10.1101/2024.02.04.24302064 DP - 2024 Jan 01 TA - medRxiv PG - 2024.02.04.24302064 4099 - http://medrxiv.org/content/early/2024/02/07/2024.02.04.24302064.short 4100 - http://medrxiv.org/content/early/2024/02/07/2024.02.04.24302064.full AB - Trachoma is the leading infectious cause of blindness worldwide and is now largely confined to around 40 low- and middle-income countries. It is caused by Chlamydia trachomatis (Ct), a contagious intracellular bacterium. The World Health Organization recommends mass drug administration (MDA) with azithromycin for treatment and control of ocular Ct infections. To understand the molecular epidemiology of trachoma, especially in the context of MDA and transmission dynamics, the identification of Ct genotypes is a necessity. While many studies have used the Ct major outer membrane protein (ompA) for genotyping, it has limitations.Our study applies a novel typing system, Multiple Loci Variable Number Tandem Repeat Analysis combined with ompA (MLVA-ompA). Ocular swabs were collected post-MDA from four trachoma-endemic zones in Ethiopia between 2011-2017. DNA from 300 children with high Ct polymerase chain reaction (PCR) loads was typed using MLVA-ompA, utilizing three variable number tandem repeat (VNTR) loci within the Ct genome.Results show that MLVA-ompA exhibited high discriminatory power (0.981) surpassing the recommended threshold for epidemiological studies. We identified 87 MLVA-ompA variants across 26 districts. No significant associations were found between variants and clinical signs or chlamydial load. Notably, overall Ct diversity significantly decreased after additional MDA rounds, with a higher proportion of serovar A post-MDA.Despite challenges in sequencing one VNTR locus (CT1299), MLVA-ompA demonstrated cost-effectiveness and efficiency relative to whole genome sequencing, providing valuable information for trachoma control programs on local epidemiology. The findings suggest the potential of MLVA-ompA as a reliable tool for typing ocular Ct and understanding transmission dynamics, aiding in the development of targeted interventions for trachoma control.Author Summary Trachoma is the leading infectious cause of blindness worldwide and is largely confined to low- and middle-income countries. It is caused by Chlamydia trachomatis (Ct), a contagious intracellular bacterium. The World Health Organization recommends mass drug administration (MDA) with the antibiotic azithromycin for treatment of ocular Ct infections. In most regions MDA is successfully reducing trachoma prevalence to the point where it is no longer a public health issue, however in some places trachoma persists despite multiple rounds of treatment. To investigate why trachoma persists, especially in the context of MDA and transmission dynamics, the identification of Ct genotypes is necessary. Our study applies a novel Ct typing system, which augments the standard method by adding three loci with high mutation rates. Results show that the novel typing system was able to discriminate between variants with greater resolution than the standard method, and was both cost-effective and more efficient relative to the gold-standard of whole genome sequencing. The findings suggest that this novel method is a reliable tool for typing ocular Ct, which can aid in the development of targeted interventions for trachoma control.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work received financial support from the Coalition for Operational Research on Neglected Tropical Diseases which is funded at the Task Force for Global Health by the Bill &amp; Melinda Gates Foundation the United Kingdom Department for International Development and the United States Agency for International Development. Additional financial support was received from the International Trachoma Initiative. EGs salary is funded by the Austrian Science Fund (FWF)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethical approvals associated with the collection and processing of these samples have been described previously. Survey methods were reviewed and approved by the Emory University Institutional Review Board (protocol 079 2006) as well as by the Amhara Regional Health Bureau. Due to elevated levels of illiteracy within the community, permission was granted for obtaining verbal consent or assent. Electronic recording of oral consent or assent was implemented for all individuals, aligning with the principles outlined in the Declaration of Helsinki. Participants had the option to conclude the examination at any juncture without the need for providing an explanation.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors